40 results on '"Lassen, U.N."'
Search Results
2. 81P Implementing genomic profiling as standard-of-care for glioblastoma patients
3. 463P Efficacy and safety of larotrectinib in a pooled analysis of patients (Pts) with tropomyosin receptor kinase (TRK) fusion cancer with an extended follow-up
4. 464P Intra-patient (Pt) comparison from larotrectinib (Laro) clinical trials in tropomyosin receptor kinase (TRK) fusion cancer: An expanded dataset
5. EP08.02-148 Extended Follow-up of Efficacy and Safety of Larotrectinib in Patients With TRK Fusion Lung Cancer
6. 1350P Bridging the platforms of adaptive clinical trials in oncology and accelerating clinical research in rare genomic aberrations
7. 61P Updated efficacy and ctDNA analysis of patients with TRK fusion lung cancer treated with larotrectinib
8. 104P Matching-adjusted indirect comparison for treatment of NTRK fusion cancer with larotrectinib versus entrectinib
9. 534P Larotrectinib in non-CNS TRK fusion cancer patients: Outcomes by prior therapy and performance status
10. 391P Detrimental effect on overall survival of CDK4/6 inhibitor dose reduction if immortal time bias is considered
11. 1711P The DRUP-like clinical trials family: A distributed European trial network for equitable access to precision medicine
12. 668P Efficacy and safety of larotrectinib in a pooled analysis of patients (Pts) with tropomyosin receptor kinase (TRK) fusion cancer
13. 604TiP ON-TRK: A non-interventional study of larotrectinib in patients with TRK fusion cancer
14. 1289P Efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase (TRK) fusion lung cancer
15. 591P Distress and perceived information among patients in phase I trials and their relatives: A prospective study
16. 1955P Survival benefits of larotrectinib in an integrated dataset of patients with TRK fusion cancer
17. 542P Growth modulation index (GMI) of larotrectinib versus prior systemic treatments for TRK fusion cancer patients
18. Durability of response with larotrectinib in adult and pediatric patients with TRK fusion cancer
19. Tisotumab vedotin (TV) in patients with previously treated recurrent or metastatic cervical cancer: Updated safety and efficacy results from the full cervical cohort of the phase II innova TV 201 study (NCT02001623)
20. Larotrectinib efficacy and safety in TRK fusion cancer: An expanded clinical dataset showing consistency in an age and tumor agnostic approach
21. A first-in-class, first-in-human phase I/IIa trial of CAN04, targeting interleukin-1 receptor accessory protein (IL1RAP), in patients with solid tumors
22. A phase IIa study of tisotumab vedotin in patients with previously treated recurrent or metastatic cervical cancer: Updated analysis of full cervical expansion cohort
23. Clinical activity, safety, and PK/PD from a phase I study of RO6874281, a fibroblast activation protein (FAP) targeted interleukin-2 variant (IL-2v)
24. Phase I/II study of ODM-203, a selective dual FGFR/VEGFR inhibitor, in patients with advanced solid tumours
25. Larotrectinib efficacy and safety in TRK fusion cancer: An expanded clinical dataset showing consistency in an age and tumor agnostic approach
26. Are socioeconomic position and region of residence barriers for referral to phase I trials?
27. 535P Larotrectinib efficacy and safety in adult patients with tropomyosin receptor kinase (TRK) fusion cancer
28. 445PD - Durability of response with larotrectinib in adult and pediatric patients with TRK fusion cancer
29. 69O - Larotrectinib efficacy and safety in TRK fusion cancer: An expanded clinical dataset showing consistency in an age and tumor agnostic approach
30. 1570P - Are socioeconomic position and region of residence barriers for referral to phase I trials?
31. 1172P - A first-in-class, first-in-human phase I/IIa trial of CAN04, targeting interleukin-1 receptor accessory protein (IL1RAP), in patients with solid tumors
32. 963P - A phase IIa study of tisotumab vedotin in patients with previously treated recurrent or metastatic cervical cancer: Updated analysis of full cervical expansion cohort
33. 412PD - Clinical activity, safety, and PK/PD from a phase I study of RO6874281, a fibroblast activation protein (FAP) targeted interleukin-2 variant (IL-2v)
34. 420P - Phase I/II study of ODM-203, a selective dual FGFR/VEGFR inhibitor, in patients with advanced solid tumours
35. 409O - Larotrectinib efficacy and safety in TRK fusion cancer: An expanded clinical dataset showing consistency in an age and tumor agnostic approach
36. Multi-Arm, Nonrandomized, Open-Label Phase Ib Study to Evaluate Fp1039/Gsk3052230 with Chemotherapy in Nsclc and Mpm with Deregulated Fgf Pathway Signaling
37. Phase Ib Trial Trial of Rg7116, a Glycoengineered Monoclonal Antibody Targeting Her3, in Combination with Cetuximab or Erlotinib in Patients with Advanced/Metastatic Tumors of Epithelial Cell Origin Expressing Her3 Protein
38. 1220TiP - Multi-Arm, Nonrandomized, Open-Label Phase Ib Study to Evaluate Fp1039/Gsk3052230 with Chemotherapy in Nsclc and Mpm with Deregulated Fgf Pathway Signaling
39. 444O - Phase Ib Trial Trial of Rg7116, a Glycoengineered Monoclonal Antibody Targeting Her3, in Combination with Cetuximab or Erlotinib in Patients with Advanced/Metastatic Tumors of Epithelial Cell Origin Expressing Her3 Protein
40. How much impact had of etoposide (E) and cisplatin (P) on treatment outcome in small cell lung cancer (SCLC)? Analysis of data on limited stage disease (LD) from two decades (1973–1992)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.